MAP2K7 and neoplasm: Another approach using dasatinib [9] and trametinib [10] with GD2 CAR-T cells demonstrated increased anti-tumor activity by reducing overactivation and subsequent exhaustion of GD2 CAR-T cells, as these drugs modulate T cell receptor (TCR) activation through the inhibition of Lck or the Raf/MEK pathway.